SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Kura Oncology announced preliminary clinical data from a subset of…

Kura Oncology, Inc. · PRESS-RELEASE filed Apr 17, 2026 at 06:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 17, 2026 at 06:00 ET

Kura Oncology announced preliminary clinical data from a subset of patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib, showing a 44% objective response rate and 94% disease control rate with its investigational combination of darlifarnib and cabozantinib. The results suggest potential to overcome resistance to VEGF TKI therapy in a heavily pretreated population, with durable responses observed and a manageable safety profile. The data were presented at IKCS: Europe and discussed in a virtual investor event.

  • Preliminary data from 16 ccRCC patients previously treated with cabozantinib showed a 44% objective response rate (ORR) and 94% disease control rate (DCR).
  • Tumor shrinkage occurred in 75% of patients, with reductions ranging from 32% to 47% among responders.
  • Treatment durations ranged up to 56 weeks, with one-third of patients still on therapy at data cutoff.
  • Darlifarnib is being evaluated in combination with cabozantinib in the ongoing FIT-001 trial, with dose expansion underway.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access